1 Cathie Wood Stock That Could Double Your Money
Cathie Wood's Ark Investment Management has deemed CRISPR/Cas 9 genome editing as "biotech's breakthrough of the century." Back in 2018, Ark identified this gene-editing tool as a potential $2 trillion-a-year opportunity, thanks to its potential to disrupt the treatment of 10,000 monogenic human diseases, aquaculture, and medical diagnostics.
After a dramatic sell-off in CRISPR/Cas 9 gene-editing stocks during the 2022 bear market, Wood's flagship fund has been steadily buying shares of Intellia Therapeutics (NASDAQ: NTLA) in 2023. Intellia is the second most advanced CRISPR/Cas9 player among the space's small contingent of publicly traded companies.
Source Fool.com
Intellia Therapeutics Inc Stock
Intellia Therapeutics Inc is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
Based on the current price of 22.76 € the target price of 60 € shows a potential of 163.62% for Intellia Therapeutics Inc which would more than double the current price.